Bcl-2 engineered MSCs inhibited apoptosis and improved heart function

Stem Cells

Volumn 25, Issue 8, 2007, Pages 2118-2127

  Li, Wenzhong ^a   Ma, Nan ^a   Ong, Lee Lee ^a   Nesselmann, Catharina ^a   Klopsch, Christian ^a   Ladilov, Yury ^a   Furlani, Dario ^a   Piechaczek, Christoph ^b   Moebius, Jeannette M ^b   Lützow, Karola ^c   Lendlein, Andreas ^c   Stamm, Christof ^d   Li, Ren Ke ^e   Steinhoff, Gustav ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b MILTENYI BIOTEC GMBH   (Germany)

^c INSTITUTE OF MATERIALS RESEARCH   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Antiapoptosis; Gene therapy; Stem cells; Transplantation

Indexed keywords

PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CELL SURVIVAL; CONTROLLED STUDY; DNA MODIFICATION; ENGRAFTMENT; GENE EXPRESSION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; IN VITRO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MESENCHYMAL STEM CELL; NONHUMAN; RAT; REVASCULARIZATION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL HYPOXIA; CELLS, CULTURED; GENES, BCL-2; HEART; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; ORGANISMS, GENETICALLY MODIFIED; RATS; RATS, INBRED LEW; REGENERATION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; RATTUS;

EID: 34547901409     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0771     Document Type: Article

References (59)

1. Leor J, Patterson M, Quinones MJ et al. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium? Circulation 1996;94(suppl 9):332-336.
2. Min JY, Yang Y, Sullivan MF et al. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg 2003;125:361-369.
3. Murry CE, Wiseman RW, Schwartz SM et al. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 1996;98:2512-2523.
4. Taylor DA, Atkins BZ, Hungspreugs P et al. Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. Nat Med 1998;4:929-933.
5. Jia ZQ, Mickle DA, Weisel RD et al. Transplanted cardiomyocytes survive in scar tissue and improve heart function. Transplant Proc 1997;29:2093-2094.
6. Li RK, Jia ZQ, Weisel RD et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996;62:654-660.
7. Li RK, Jia ZQ, Weisel RD et al. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol 1999;31:513-522.
8. Yoo KJ, Li RK, Weisel RD et al. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg 2000;70:859-865.
9. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005;85:1373-1416.
10. Tomita S, Li RK, Weisel RD et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999;100(suppl 19):247-256.
11. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-436.
12. Li RK, Mickle DA, Weisel RD et al. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann Thorac Surg 2001;72:1957-1963.
13. Stamm C, Westphal B, Kleine HD et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003;361:45-46.
14. Menasche P, Hagege AA, Vilquin JT et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003;41:1078-1083.
15. Assmus B, Schachinger V, Teupe C et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017.
16. Ma N, Ladilov Y, Moebius JM et al. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells. Cardiovasc Res 2006;71:158-169.
17. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20.
18. Mangi AA, Noiseux N, Kong D et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201.
19. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
20. Pereira RF, Halford KW, O'Hara MD et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A 1995;92:4857-4861.
21. Chen J, Li Y, Wang L et al. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 2001;189:49-57.
22. Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998;279:1528-1530.
23. Makino S, Fukuda K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999;103:697-705.
24. Toma C, Pittenger MF, Cahill KS et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-98.
25. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-896.
26. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-3844.
27. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bonemarrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141-148.
28. Zhang M, Methot D, Poppa V et al. Cardiomyocyte grafting for cardiac repair: Graft cell death and anti-death strategies. J Mol Cell Cardiol 2001;33:907-921.
29. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-1911.
30. Reed JC. Bcl-2 family proteins. Oncogene 1998;17:3225-3236.
31. Misao J, Hayakawa Y, Ohno M et al. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation 1996;94:1506-1512.
32. Feuerstein G, Ruffolo RR Jr., Yue TL. Apoptosis and congestive heart failure. Trends Cardiovasc Med 1997;7:249-255.
33. Liu L, Azhar G, Gao W et al. Bcl-2 and Bax expression in adult rat hearts after coronary occlusion: Age-associated differences. Am J Physiol 1998;275:R315-R322.
34. Kirshenbaum LA, de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation 1997;96:1580-1585.
35. Murphy AN, Bredesen DE, Cortopassi G et al. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci U S A 1996;93:9893-9898.
36. Nunez G, London L, Hockenbery D et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-3610.
37. Veis DJ, Sorenson CM, Shutter JR et al. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993;75:229-240.
38. Imahashi K, Schneider MD, Steenbergen C et al. Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury. Circ Res 2004;95:734-741.
39. Chen Z, Chua CC, Ho YS et al. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 2001;280:H2313-H2320.
40. Palojoki E, Saraste A, Eriksson A et al. Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2001;280:H2726-H2731.
41. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
42. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977;91:335-344.
43. Barry F, Boynton RE, Liu B et al. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: Differentiation-dependent gene expression of matrix components. Exp Cell Res 2001;268:189-200.
44. Brocheriou V, Hagege AA, Oubenaissa A et al. Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/ reperfusion injury. J Gene Med 2000;2:326-333.
45. Geng YJ. Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Ann N Y Acad Sci 2003;1010:687-697.
46. Tang YL, Tang Y, Zhang YC et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005;46:1339-1350.
47. Lee RJ, Springer ML, Blanco-Bose WE et al. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 2000;102:898-901.
48. Yoon YS, Wecker A, Heyd L et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005;115:326-338.
49. Tang YL, Zhao Q, Qin X et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 2005;80:229-236.
50. Gnecchi M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-368.
51. Uemura R, Xu M, Ahmad N et al. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006;98:1414-1421.
52. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001;103:634-637.
53. Nagaya N, Fujii T, Iwase T et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 2004;287:H2670-H2676.
54. Chen J, Zhang ZG, Li Y et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 2003;92:692-699.
55. Matsushita H, Morishita R, Nata T et al. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: In vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res 2000;86:974-981.
56. Regula KM, Baetz D, Kirshenbaum LA. Nuclear factor-kappaB represses hypoxia-induced mitochondrial defects and cell death of ventricular myocytes. Circulation 2004;110:3795-3802.
57. Berry MF, Engler AJ, Woo YJ et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol 2006;290:H2196-H2203.
58. Amado LC, Saliaris AP, Schuleri KH et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005;102:11474-11479.
59. Ma N, Wu SS, Ma YX et al. Nerve growth factor receptor-mediated gene transfer. Mol Ther 2004;9:270-281.